<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520454</url>
  </required_header>
  <id_info>
    <org_study_id>2009P000370</org_study_id>
    <nct_id>NCT01520454</nct_id>
  </id_info>
  <brief_title>Effect of Increased Free Fatty Acids on Leptin Function</brief_title>
  <official_title>Differential Effects of Oral and Intravenous Lipid Administration on Leptin Signaling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obese people have elevated levels of the hormone leptin. Despite this, they seem to be
      resistant to the effects of this hormone, which usually regulates appetite and energy
      expenditure. This is similar to what happens with insulin levels in the obese. Furthermore,
      the way lipid ingestion versus lipid infusion may impact novel molecules secreted by tissues
      commonly affected in insulin resistant states such as liver and muscle have not yet been
      studied.

      The aim of the present study is to investigate the effect of oral vs. different doses of IV
      lipid administration on molecular parameters related to glucose and energy homeostasis using
      a randomized, placebo-controlled design.

      Additionally, we will examine how increased free fatty acids (FFAs) my impact intracellular
      leptin signaling such as the STAT3 pathway.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to test our hypotheses by conducting a non-blinded, interventional study
      evaluating the effects of acute leptin administration on intracellular leptin signaling
      pathways after a 6 hour infusion period comparing an oral high fat meal, high fat lipid
      infusion, low fat lipid infusion, or placebo infusion (saline)iv lipid infusion, placebo
      (saline) and oral high fat meal. After a screening visit, study participation involves 1 meal
      pick-up visit, 1 overnight visit, and one 1 follow-up visit. Subjects will be randomized to
      one of 4 groups: an oral high fat meal, fat emulsion 20% infusion , fat emulsion 10%
      infusion, and a placebo (saline) infusion infusion and an oral high fat meal.

      We plan to screen 100 male and postmenopausal female subjects, with BMI greater than 18
      kg/m2, to consent 60 in order to have 32-48 evaluable subjects, 8-12 subjects per group,
      completing all parts of the study.

      The primary study outcome to be evaluated will be the changes in serum concentrations of
      glucose, hormones influencing metabolism such as insulin, fat-cell-secreted proteins such as
      leptin, molecules involved in metabolism such as free fatty acids (FFAs), and markers of
      inflammation such as interleukin (IL)-2 and interferon (IFN)-gamma.

      The secondary outcome will be to examine the impacts of increased FFAs on intracellular
      leptin signaling by phosphorylation of STAT3.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The GLP-1 area under the curve (AUC) was calculated from baseline to six hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Circulating Gastric Inhibitory Polypeptide (GIP) Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The GIP AUC fwas calculated from baseline to six hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Circulating Ghrelin Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The Ghrelin AUC was calculated from baseline to six hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Circulating Peptide Tyrosine Tyrosine (PYY) Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The PYY AUC was calculated from baseline to six hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Glucose Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The Glucose AUC was calculated from baseline to six hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Insulin Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The Insulin AUC was calculated from baseline to six hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Leptin Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The Leptin AUC was calculated from baseline to six hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Circulating Adiponectin Levels</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>The Adiponectin AUC was calculated from baseline to six hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phosphorylation of STAT3 Pathways Downstream of Leptin After Lipid Administration</measure>
    <time_frame>Baseline to 6 hours</time_frame>
    <description>Intracellular signaling mechanisms downstream of leptin (particularly the STAT3 pathway) in response to lipid administration as represented by phosphorylation (pSTAT3).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Obesity</condition>
  <condition>Leptin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV saline with heparin, oral water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose fat solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intralipid at high dose, with heparin and PO water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose fat solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose IV Intralipid with heparin and PO water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral fat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral fat load with IV saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>IV saline at 0.83 mL/kg/hr for six hours</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Oral fat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours</description>
    <arm_group_label>High dose fat solution</arm_group_label>
    <arm_group_label>Low dose fat solution</arm_group_label>
    <other_name>intravenous lipids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Water</intervention_name>
    <description>Water by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>High dose fat solution</arm_group_label>
    <arm_group_label>Low dose fat solution</arm_group_label>
    <arm_group_label>Oral fat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>oral fat</intervention_name>
    <description>Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
    <arm_group_label>Oral fat</arm_group_label>
    <other_name>soybean oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>High dose fat solution</arm_group_label>
    <arm_group_label>Low dose fat solution</arm_group_label>
    <other_name>anti coated</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

        Exclusion Criteria:

          1. Subjects with a history of any illness, other than obesity, that may affect insulin
             sensitivity (anemia, infectious diseases, renal or hepatic failure, uncontrolled
             hypertension, cancer, lymphoma, chronic inflammatory conditions such as inflammatory
             bowel disease and rheumatoid arthritis, states of cortisol or growth hormone excess,
             alcoholism or drug abuse, and eating disorders).

          2. History of diabetes mellitus.

          3. Subjects taking any medications that are known to influence glucose metabolism such as
             glucocorticoids will also be excluded. We will screen for these conditions by means of
             a detailed history and review of systems and physical examination (see below).

          4. Subjects taking any medications known to affect lipids such as statins will also be
             excluded. We will screen for these similar to above.

          5. Cholesterol greater or equal to 250 mg/dL and/or triglyceride levels greater than 500
             mg/dL at the time of screening, as determined by laboratory testing.

          6. Subjects who have a known history of anaphylaxis or anaphylactoid-like reactions or
             who have a known hypersensitivity to anesthetic agents such as Lidocaine or Marcaine
             will be excluded from the study.

          7. Hypersensitivity to fat emulsion or any component of the formulation; severe egg or
             legume (soybean) allergies; pathologic hyperlipidemia, lipoid nephrosis, acute
             pancreatitis associated with hyperlipemia.

          8. Hypersensitivity to heparin or any component of the formulation

          9. Severe thrombocytopenia, uncontrolled active bleeding, disseminated intravascular
             coagulation (DIC); suspected intracranial hemorrhage.

         10. Subjects with a history of bleeding dyscrasia, poor wound healing or any medical
             condition precluding supine position will be excluded from the study.

         11. Unable to follow study protocol or any condition that in the opinion of the
             investigator makes the subject unsuitable for the study.

         12. Pregnancy

         13. Prior history of gastrectomy, gastric bypass surgery, or other weight loss surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos S Mantzoros, MD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bidmc.org/Research/Departments/Medicine/Divisions/Endocrinology/Laboratories/MantzorosLab.aspx</url>
    <description>Mantzoros Lab Home Page</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2012</study_first_posted>
  <results_first_submitted>December 29, 2015</results_first_submitted>
  <results_first_submitted_qc>March 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 26, 2017</results_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Christos Mantzoros</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Leptin resistance</keyword>
  <keyword>Free fatty acids</keyword>
  <keyword>Lipotoxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours</description>
        </group>
        <group group_id="P2">
          <title>High Dose Fat Solution</title>
          <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="P3">
          <title>Low Dose Fat Solution</title>
          <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="P4">
          <title>Oral Fat</title>
          <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="B2">
          <title>High Dose Fat Solution</title>
          <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="B3">
          <title>Low Dose Fat Solution</title>
          <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="B4">
          <title>Oral Fat</title>
          <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" lower_limit="25.0" upper_limit="47.6"/>
                    <measurement group_id="B2" value="29.1" lower_limit="24.2" upper_limit="38.7"/>
                    <measurement group_id="B3" value="48.6" lower_limit="44.4" upper_limit="54.9"/>
                    <measurement group_id="B4" value="27.6" lower_limit="24.2" upper_limit="46.9"/>
                    <measurement group_id="B5" value="35.2" lower_limit="29.5" upper_limit="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels</title>
        <description>The GLP-1 area under the curve (AUC) was calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas under the curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Glucagon-like Peptide-1 (GLP-1) Levels</title>
          <description>The GLP-1 area under the curve (AUC) was calculated from baseline to six hours</description>
          <population>Areas under the curve are presented</population>
          <units>pM*min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7147" spread="3547"/>
                    <measurement group_id="O2" value="11725" spread="4799"/>
                    <measurement group_id="O3" value="11898" spread="9996"/>
                    <measurement group_id="O4" value="28060" spread="8414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Circulating Gastric Inhibitory Polypeptide (GIP) Levels</title>
        <description>The GIP AUC fwas calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas under the curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Gastric Inhibitory Polypeptide (GIP) Levels</title>
          <description>The GIP AUC fwas calculated from baseline to six hours</description>
          <population>Areas under the curve are presented</population>
          <units>pM*min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12894" spread="8803"/>
                    <measurement group_id="O2" value="11830" spread="4516"/>
                    <measurement group_id="O3" value="19386" spread="16823"/>
                    <measurement group_id="O4" value="60559" spread="36610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Circulating Ghrelin Levels</title>
        <description>The Ghrelin AUC was calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas under the curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Ghrelin Levels</title>
          <description>The Ghrelin AUC was calculated from baseline to six hours</description>
          <population>Areas under the curve are presented</population>
          <units>pg*min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172886" spread="89970"/>
                    <measurement group_id="O2" value="129451" spread="46926"/>
                    <measurement group_id="O3" value="207863" spread="111684"/>
                    <measurement group_id="O4" value="166195" spread="110140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Circulating Peptide Tyrosine Tyrosine (PYY) Levels</title>
        <description>The PYY AUC was calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas under the curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Peptide Tyrosine Tyrosine (PYY) Levels</title>
          <description>The PYY AUC was calculated from baseline to six hours</description>
          <population>Areas under the curve are presented</population>
          <units>pg*min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90016" spread="25755"/>
                    <measurement group_id="O2" value="65131" spread="14914"/>
                    <measurement group_id="O3" value="82474" spread="21072"/>
                    <measurement group_id="O4" value="144702" spread="27466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating Glucose Levels</title>
        <description>The Glucose AUC was calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas Under the Curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Glucose Levels</title>
          <description>The Glucose AUC was calculated from baseline to six hours</description>
          <population>Areas Under the Curve are presented</population>
          <units>mg*min/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30683" spread="1249"/>
                    <measurement group_id="O2" value="28735" spread="1269"/>
                    <measurement group_id="O3" value="32566" spread="1531"/>
                    <measurement group_id="O4" value="31364" spread="869"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating Insulin Levels</title>
        <description>The Insulin AUC was calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas Under the Curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Insulin Levels</title>
          <description>The Insulin AUC was calculated from baseline to six hours</description>
          <population>Areas Under the Curve are presented</population>
          <units>mU*min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1765" spread="1555"/>
                    <measurement group_id="O2" value="2072" spread="970"/>
                    <measurement group_id="O3" value="2103" spread="1645"/>
                    <measurement group_id="O4" value="3021" spread="1426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating Leptin Levels</title>
        <description>The Leptin AUC was calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas Under the Curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Leptin Levels</title>
          <description>The Leptin AUC was calculated from baseline to six hours</description>
          <population>Areas Under the Curve are presented</population>
          <units>ng*min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2050" spread="2233"/>
                    <measurement group_id="O2" value="3639" spread="4470"/>
                    <measurement group_id="O3" value="5439" spread="4671"/>
                    <measurement group_id="O4" value="4973" spread="5313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Circulating Adiponectin Levels</title>
        <description>The Adiponectin AUC was calculated from baseline to six hours</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>Areas Under the Curve are presented</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Circulating Adiponectin Levels</title>
          <description>The Adiponectin AUC was calculated from baseline to six hours</description>
          <population>Areas Under the Curve are presented</population>
          <units>ng*min/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1546442" spread="500930"/>
                    <measurement group_id="O2" value="2273306" spread="1068651"/>
                    <measurement group_id="O3" value="1778846" spread="857433"/>
                    <measurement group_id="O4" value="1970601" spread="961699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phosphorylation of STAT3 Pathways Downstream of Leptin After Lipid Administration</title>
        <description>Intracellular signaling mechanisms downstream of leptin (particularly the STAT3 pathway) in response to lipid administration as represented by phosphorylation (pSTAT3).</description>
        <time_frame>Baseline to 6 hours</time_frame>
        <population>The analysis unfortunately can not be performed due to technical reasons as STAT3 was not able to be measured in the samples/not enough volume was left to perform the appropriate tests after trouble-shooting.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours</description>
          </group>
          <group group_id="O2">
            <title>High Dose Fat Solution</title>
            <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours</description>
          </group>
          <group group_id="O3">
            <title>Low Dose Fat Solution</title>
            <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours</description>
          </group>
          <group group_id="O4">
            <title>Oral Fat</title>
            <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
          </group>
        </group_list>
        <measure>
          <title>Phosphorylation of STAT3 Pathways Downstream of Leptin After Lipid Administration</title>
          <description>Intracellular signaling mechanisms downstream of leptin (particularly the STAT3 pathway) in response to lipid administration as represented by phosphorylation (pSTAT3).</description>
          <population>The analysis unfortunately can not be performed due to technical reasons as STAT3 was not able to be measured in the samples/not enough volume was left to perform the appropriate tests after trouble-shooting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>IV saline with heparin, oral water
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="E2">
          <title>High Dose Fat Solution</title>
          <description>Intralipid at high dose, with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="E3">
          <title>Low Dose Fat Solution</title>
          <description>Low dose IV Intralipid with heparin and PO water
Intralipid: Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
Water: Water by mouth
Heparin: Heparin bolus of 1000 units followed by 800 u/hr, adjust per PTT, for 5.5 hours</description>
        </group>
        <group group_id="E4">
          <title>Oral Fat</title>
          <description>Oral fat load with IV saline
Saline: IV saline at 0.83 mL/kg/hr for six hours
Water: Water by mouth
oral fat: Soybean oil by mouth at 1.25 g/kg x 2 doses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christos Manztoros</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-8630</phone>
      <email>cmantzor@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

